Stock ONCT ONCTERNAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Market Closed - Nasdaq
Other stock markets
 21:30:01 26/04/2024 BST 		5-day change 1st Jan Change
8.29 USD +0.48% Intraday chart for Oncternal Therapeutics, Inc. -6.43% -22.70%
04-18 Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer CI
04-15 HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
AQ
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
CI
HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating
MT
Transcript : Oncternal Therapeutics, Inc. - Special Call
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
AQ
Transcript : Oncternal Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Oncternal Therapeutics: Q4 Earnings Snapshot
AQ
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
AQ
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
AQ
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science
CI
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
AQ
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
CI
Reverse Split: 1 of 20
FA
Oncternal Therapeutics Announces Reverse Stock Split
AQ
Oncternal Therapeutics Reports Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCT Stock
  4. News Oncternal Therapeutics, Inc.